
Robert Daniel Beauchamp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6437314/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Research, 1998, 58, 362-6.	0.9	843
2	Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2 Journal of Clinical Investigation, 1997, 99, 2254-2259.	8.2	612
3	Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. Journal of Clinical Investigation, 2005, 115, 1765-1776.	8.2	456
4	A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 1486-1490.	7.1	372
5	Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21WAF1/CIP1 via C/EBPβ. Nature Medicine, 1997, 3, 1233-1241.	30.7	309
6	Regulation of intestinal epithelial cell growth by transforming growth factor type beta Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 1578-1582.	7.1	308
7	Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 1996, 111, 1134-1140.	1.3	276
8	A Specific Inhibitor of TGF-β Receptor Kinase, SB-431542, as a Potent Antitumor Agent for Human Cancers. Neoplasia, 2005, 7, 509-521.	5.3	239
9	Localization of transforming growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid secretion and mucosal renewal Journal of Clinical Investigation, 1989, 84, 1017-1023.	8.2	231
10	Regulation of Cyclooxygenase-2 Expression by the Translational Silencer TIA-1. Journal of Experimental Medicine, 2003, 198, 475-481.	8.5	190
11	Transforming Growth Factor-β1 Enhances Ha-ras-induced Expression of Cyclooxygenase-2 in Intestinal Epithelial Cells via Stabilization of mRNA. Journal of Biological Chemistry, 2000, 275, 6628-6635.	3.4	175
12	18Fluorodeoxyglucose-Positron Emission Tomography in the Management of Patients With Suspected Pancreatic Cancer. Annals of Surgery, 1999, 229, 729.	4.2	170
13	A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology, 1997, 113, 1883-1891.	1.3	164
14	Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling. Gut, 2014, 63, 622-634.	12.1	163
15	Induction of Cyclooxygenase-2 by Activated Ha-rasOncogene in Rat-1 Fibroblasts and the Role of Mitogen-activated Protein Kinase Pathway. Journal of Biological Chemistry, 1998, 273, 22120-22127.	3.4	161
16	Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Research, 2001, 61, 5389-95.	0.9	144
17	Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated with human colorectal adenocarcinomas. Journal of Clinical Investigation, 2010, 120, 840-849.	8.2	134
18	Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Oncogene, 2011, 30, 3234-3247.	5.9	133

#	Article	IF	CITATIONS
19	Smad7 induces tumorigenicity by blocking TGF-β-induced growth inhibition and apoptosis. Experimental Cell Research, 2005, 307, 231-246.	2.6	117
20	Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene, 1995, 10, 177-84.	5.9	113
21	Resident Work Hour Limits and Patient Safety. Annals of Surgery, 2005, 241, 847-860.	4.2	111
22	Oncogenic Ras Represses Transforming Growth Factor-β/Smad Signaling by Degrading Tumor Suppressor Smad4. Journal of Biological Chemistry, 2001, 276, 29531-29537.	3.4	106
23	Proglumide, A Gastrin Receptor Antagonist, Inhibits Growth of Colon Cancer and Enhances Survival in Mice. Annals of Surgery, 1985, 202, 303-309.	4.2	104
24	Nuclear Factor of Activated T-cell Activity Is Associated with Metastatic Capacity in Colon Cancer. Cancer Research, 2014, 74, 6947-6957.	0.9	96
25	Lymphatic Mapping and Sentinel Lymphadenectomy After Preoperative Therapy for Stage II and III Breast Cancer. Annals of Surgical Oncology, 2003, 10, 616-621.	1.5	92
26	Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Research, 1997, 57, 169-75.	0.9	89
27	Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene, 2010, 29, 3703-3714.	5.9	88
28	HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene, 2010, 29, 305-312.	5.9	83
29	Vascular Endothelial Growth Factor-Mediated Angiogenesis Inhibition and Postoperative Wound Healing in Rats. Journal of Surgical Research, 2002, 105, 43-47.	1.6	81
30	TGF-Î ² 1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression. Oncogene, 1998, 16, 3445-3454.	5.9	77
31	Oncogenic Function of a Novel WD-Domain Protein, STRAP, in Human Carcinogenesis. Cancer Research, 2006, 66, 6156-6166.	0.9	77
32	Claudin-7 expression induces mesenchymal to epithelial transformation (MET) to inhibit colon tumorigenesis. Oncogene, 2015, 34, 4570-4580.	5.9	75
33	Transforming Growth Factor- $\hat{1}^21$ Promotes Invasiveness after Cellular Transformation with Activated Ras in Intestinal Epithelial Cells. Experimental Cell Research, 2001, 266, 239-249.	2.6	74
34	Urine PGE-M: A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia. Clinical Gastroenterology and Hepatology, 2006, 4, 1358-1365.	4.4	74
35	Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut, 2012, 61, 1291-1298.	12.1	74
36	Receptorâ€mediated autocrine growthâ€stimulatory effect of 5â€hydroxytryptamine on cultured human pancreatic carcinoid cells. Journal of Cellular Physiology, 1992, 150, 1-7.	4.1	72

#	Article	IF	CITATIONS
37	Coordinate regulation of cyclooxygenase-2 and TGF-1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis, 1999, 20, 185-191.	2.8	72
38	Synergistic Induction of Cyclooxygenase-2 by Transforming Growth Factor-β1 and Epidermal Growth Factor Inhibits Apoptosis in Epithelial Cells. Neoplasia, 1999, 1, 508-517.	5.3	72
39	XIAP Monoubiquitylates Groucho/TLE to Promote Canonical Wnt Signaling. Molecular Cell, 2012, 45, 619-628.	9.7	72
40	Nuclear translocation of beta-catenin in hereditary and carcinogen- induced intestinal adenomas. Carcinogenesis, 1998, 19, 543-549.	2.8	71
41	Smad4 Regulates Claudin-1 Expression in a Transforming Growth Factor-β–Independent Manner in Colon Cancer Cells. Cancer Research, 2007, 67, 1571-1579.	0.9	71
42	Oncogenic Ras-mediated Cell Growth Arrest and Apoptosis are Associated with Increased Ubiquitin-dependent Cyclin D1 Degradation. Journal of Biological Chemistry, 2000, 275, 22916-22924.	3.4	70
43	Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer. Clinical Cancer Research, 2006, 12, 1570-1576.	7.0	67
44	Expression of and Response to Growth Regulatory Peptides by Two Human Pancreatic Carcinoma Cell Lines. Pancreas, 1990, 5, 369-380.	1.1	66
45	Posttranscriptional Regulation of Cyclooxygenase-2 in Rat Intestinal Epithelial Cells. Neoplasia, 2000, 2, 523-530.	5.3	63
46	BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. Journal of Clinical Investigation, 2011, 121, 4056-4069.	8.2	60
47	Transformation of intestinal epithelial cells by chronic TGF-β1 treatment results in downregulation of the type II TGF-β receptor and induction of cyclooxygenase-2. Oncogene, 1999, 18, 855-867.	5.9	58
48	Fibrogenesis in pancreatic cancer is a dynamic process regulated by macrophage–stellate cell interaction. Laboratory Investigation, 2014, 94, 409-421.	3.7	58
49	Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1. Gastroenterology, 2019, 156, 662-675.e7.	1.3	56
50	Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Research, 1991, 51, 5253-60.	0.9	54
51	Growth factors and intestinal neoplasms. American Journal of Surgery, 1988, 155, 526-536.	1.8	51
52	Role of Smad proteins in the regulation of NF-κB by TGF-β in colon cancer cells. Cellular Signalling, 2006, 18, 1041-1050.	3.6	43
53	TGF-? and colorectal carcinogenesis. Microscopy Research and Technique, 2001, 52, 450-457.	2.2	42
54	A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nature Biotechnology, 2003, 21, 771-777.	17.5	42

#	Article	IF	CITATIONS
55	Smad4-dependent Regulation of Urokinase Plasminogen Activator Secretion and RNA Stability Associated with Invasiveness by Autocrine and Paracrine Transforming Growth Factor-β. Journal of Biological Chemistry, 2006, 281, 33971-33981.	3.4	42
56	Transforming growth factor-Î ² inhibits rat intestinal cell growth by regulating cell cycle specific gene expression. American Journal of Surgery, 1994, 167, 14-20.	1.8	40
57	Oncogenic Ras and Transforming Growth Factor-β Synergistically Regulate AU-Rich Element–Containing mRNAs during Epithelial to Mesenchymal Transition. Molecular Cancer Research, 2008, 6, 1124-1136.	3.4	38
58	Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-p16INK4A fusion peptide in pancreatic cancer cells. Cancer Letters, 2000, 159, 151-158.	7.2	37
59	Smad3 has a critical role in TGF-β-mediated growth inhibition and apoptosis in colonic epithelial cells. Journal of Surgical Research, 2004, 117, 296-305.	1.6	36
60	Identification and Optimization of Small Molecules That Restore E-Cadherin Expression and Reduce Invasion in Colorectal Carcinoma Cells. ACS Chemical Biology, 2011, 6, 452-465.	3.4	35
61	A Network-Based Gene Expression Signature Informs Prognosis and Treatment for Colorectal Cancer Patients. PLoS ONE, 2012, 7, e41292.	2.5	35
62	Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome. Cancer Research, 2013, 73, 2955-2964.	0.9	34
63	Enhanced Tumor Formation in Cyclin D1 × Transforming Growth Factor β1 Double Transgenic Mice with Characterization by Magnetic Resonance Imaging. Cancer Research, 2004, 64, 1315-1322.	0.9	27
64	Four Jointed Box 1 Promotes Angiogenesis and Is Associated with Poor Patient Survival in Colorectal Carcinoma. PLoS ONE, 2013, 8, e69660.	2.5	27
65	New Strategies for Colorectal Cancer Prevention and Treatment. World Journal of Surgery, 2002, 26, 762-766.	1.6	26
66	Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Cancer Research, 1997, 57, 1638-43.	0.9	25
67	Identification of Early Intestinal Neoplasia Protein Biomarkers Using Laser Capture Microdissection and MALDI MS. Molecular and Cellular Proteomics, 2009, 8, 936-945.	3.8	24
68	Adenomaâ€like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance onÂbiopsy and frequent <i><scp>KRAS</scp></i> mutation. Histopathology, 2016, 68, 183-190.	2.9	23
69	Colon epithelial cell TGFβ signaling modulates the expression of tight junction proteins and barrier function in mice. American Journal of Physiology - Renal Physiology, 2021, 320, G936-G957.	3.4	23
70	Kaiso Directs the Transcriptional Corepressor MTG16 to the Kaiso Binding Site in Target Promoters. PLoS ONE, 2012, 7, e51205.	2.5	22
71	Intestinal Cell Cycle Regulation. Annals of Surgery, 1996, 223, 620-628.	4.2	21
72	Role of cholecystokinin in canine pancreatic exocrine response to bombesin stimulation. American Journal of Surgery, 1987, 153, 96-101.	1.8	20

#	Article	IF	CITATIONS
73	Unexpected growth-stimulatory effect of somatostatin analogue on cultured human pancreatic carcinoid cells. Biochemical and Biophysical Research Communications, 1992, 185, 577-581.	2.1	18
74	Dysregulation of E-cadherin by oncogenic ras in intestinal epithelial cells is blocked by inhibiting MAP kinase. American Journal of Surgery, 2003, 186, 426-430.	1.8	18
75	Induction of Cyclooxygenase-2 and Invasiveness by Transforming Growth Factor-β1 in Immortalized Mouse Colonocytes Expressing Oncogenic Ras,. Journal of Gastrointestinal Surgery, 2002, 6, 304-309.	1.7	15
76	Deciphering Genomic Alterations in Colorectal Cancer through Transcriptional Subtype-Based Network Analysis. PLoS ONE, 2013, 8, e79282.	2.5	15
77	Phenotypic alterations in fibroblasts and fibrosarcoma cells that overexpress latent transforming growth factor-beta 1 Endocrinology, 1992, 130, 2476-2486.	2.8	13
78	Transforming Growth Factor (TGF)-β Stimulates Hepatic and Proto-oncogenes and Decreases Albumin mRNA. Annals of Surgery, 1992, 216, 300-308.	4.2	11
79	Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. Oncotarget, 2015, 6, 22934-22948.	1.8	11
80	Posttranscriptional regulation of albumin and alpha-fetoprotein messenger RNA by transforming growth factor-beta 1 requires de novo RNA and protein synthesis Molecular Endocrinology, 1992, 6, 1789-1796.	3.7	10
81	Over-expression of cyclin D1 regulates Cdk4 protein synthesis. Cell Proliferation, 2003, 36, 347-360.	5.3	10
82	A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. Investigational New Drugs, 2001, 19, 21-27.	2.6	9
83	A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Radiotherapy and Oncology, 2005, 76, 54-58.	0.6	9
84	Cyclin D3 Is Essential for Intestinal Epithelial Cell Proliferation. World Journal of Surgery, 2002, 26, 812-818.	1.6	8
85	Posttranscriptional regulation of albumin and alpha-fetoprotein messenger RNA by transforming growth factor-beta 1 requires de novo RNA and protein synthesis. Molecular Endocrinology, 1992, 6, 1789-1796.	3.7	8
86	Differential regulation by TGF-beta 1 and insulin of insulin-like growth factor binding protein-2 in IEC-6 cells. American Journal of Physiology - Endocrinology and Metabolism, 1995, 268, E1199-E1204.	3.5	6
87	Operative strategies in the management of mediastinal pancreatic pseudocyst. Surgery, 1989, 106, 567-70.	1.9	6
88	A High Pressure Liquid Chromatography-Radioimmunoassay Method for Measurement of Cholecystokinin-8 and Cholecystokinin-33/39 in Plasma. Journal of Liquid Chromatography and Related Technologies, 1987, 10, 1431-1438.	1.0	5
89	Differential Effects of Sodium Butyrate and Hexamethylene Bisacetamide on Growth and Secretion of Cultured Human Endocrine Tumor Cells. Archives of Surgery, 1991, 126, 467.	2.2	5
90	The role of endogenous prostaglandins in hormone-stimulated pancreatic exocrine secretion. Gastroenterology, 1992, 102, 272-279.	1.3	4

#	Article	IF	CITATIONS
91	Short-term caloric restriction augments age-related decreases in gastrin content and release. Mechanisms of Ageing and Development, 1996, 87, 25-33.	4.6	3
92	Presidential address: Evolution. Surgery, 2000, 128, 123-132.	1.9	3
93	Systemic alterations in ornithine decarboxylase activity caused by colon cancer in mice. Cancer Letters, 1991, 58, 155-158.	7.2	2
94	Activation of hepatic proliferation-associated transcription factors by lipopolysaccharide. Surgery, 1994, 116, 367-76; discussion 376-7.	1.9	1
95	Roles for transforming growth factor-α and transforming growth factor-ß in colorectal cancer. Current Colorectal Cancer Reports, 2006, 2, 72-77.	0.5	0
96	Proglumide inhibits cholecystokinin and meal-stimulated pancreatic secretion and release of pancreatic polypeptide. Surgery, 1990, 108, 553-8.	1.9	0